Nordea s Main Owner Sampo to Materially Cut Stake in Bank msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Swedish King Says Nation’s Controversial Covid Plan Failed Bloomberg 12/17/2020 Charles Daly, Rafaela Lindeberg and Niclas Rolander
(Bloomberg) Swedes are rapidly losing faith in their country’s response to the pandemic, with even the King delivering a rare rebuke to those in charge.
Significantly more Swedes have gotten sick and died from Covid-19 than elsewhere in the Nordic region. And with Stockholm recently almost running out of intensive care beds, frustration levels are high.
“The Swedish people have suffered enormously in difficult conditions,” King Carl XVI Gustaf told state broadcaster SVT. When it comes to the strategy deployed in Sweden, he said, “I think we have failed.”
Swedish King Says Nation’s Controversial Covid Plan Failed
Bloomberg 12/17/2020 Charles Daly, Rafaela Lindeberg and Niclas Rolander
(Bloomberg) Swedes are rapidly losing faith in their country’s response to the pandemic, with even the King delivering a rare rebuke to those in charge.
Significantly more Swedes have gotten sick and died from Covid-19 than elsewhere in the Nordic region. And with Stockholm recently almost running out of intensive care beds, frustration levels are high.
“The Swedish people have suffered enormously in difficult conditions,” King Carl XVI Gustaf told state broadcaster SVT. When it comes to the strategy deployed in Sweden, he said, “I think we have failed.”
Saturday’s deal by
Alexion Pharmaceuticals brings a franchise in rare immune disorders to Astra, while also bringing to a close a campaign by discontented Alexion stockholders to get the company sold.
AstraZeneca’s $39 billion payment in cash and stock was valued at $175 per share of Alexion, and the stock of Alexion (ticker: ALXN) jumped 30% on Monday’s open, to $157. Shares of AstraZeneca (AZN) slipped 6.3%, however, to $50.88.
The deal will just about use up AstraZeneca’s capital available for deal-making. Investors have mixed feelings.
Although Alexion enjoys strong cash flow from treatments for disorders in a part of the immune system known as the complement, SVB Leerink analyst Andrew Berens raised concerns about expiring patents on Alexion’s big-selling drug Soliris. He said, though, that before that becomes a problem, the addition of Alexion could nearly double AstraZeneca’s cash flow in the next five years.